Latest Intelligence on Infectious Diseases

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

"GreeneChip": new tool with broad use

A novel diagnostic tool, able to simultaneously screen for up to 30,000 different viruses, bacteria, fungi and parasites is currently being investigated by researchers at New York's Columbia University. Although its widespread availability requires more work, such a tool could help physicians give a more accurate diagnosis and prescribe appropriate treatment.

Published By Datamonitor
13 Dec 2006
CommentWire
CommentWire

Abbott: AIDS group lawsuit attracts negative publicity

Abbott Laboratories has sued a French AIDS activist group, Act Up Paris, for launching a cyber attack against its website. This comes as a surprise to the industry which, after years of negative publicity generated by AIDS activists, is investing a great deal of effort in working with patient advocacy groups.

Published By Datamonitor
20 Jun 2007
CommentWire
CommentWire

Acambis: leading the pack on West Nile fever vaccine

Concern is rising in parts of the US that a West Nile fever outbreak could cause an epidemic worse than that experienced in 2004, due to a wet spring and diminishing immunity in the bird population. The increasing impact of the West Nile Virus since its arrival in the US in 2000 highlights the need for a preventative vaccine, with Acambis [ACM.L] leading the race to bring one to market.

Published By Datamonitor
25 May 2005
CommentWire
CommentWire

Accentia: uncertain role for SinuNase

Accentia believes that it has evidence to support a theory that most, if not all, cases of chronic sinusitis are caused by fungal-induced inflammation. Preliminary analysis of samples taken as part of a Phase III trial for one of the company's developmental compounds suggest a link, but the role of the drug in disease management is less clear.

Published By Datamonitor
11 Sep 2007
CommentWire
CommentWire

Advanced Life Sciences: aiming for second place with cethromycin

Considering the strong launch of the only ketolide currently available, Sanofi-Aventis' Ketek, Advanced Life Sciences' antibiotic cethromycin is expected to perform well in its first few years on the market, once approved. Indeed, with off-label use, cethromycin revenues could reach $145 million by 2010, beating Wall Street consensus of $123 million. However, Ketek will remain a formidable rival.

Published By Datamonitor
14 Jun 2006
ResearchWire
ResearchWire

Advanced Life Sciences: aiming for second place with cethromycin

Published By Datamonitor
30 Jun 2006
CommentWire
CommentWire

African HIV: more research needed, says Mandela

According to Nelson Mandela, further research is required into the effects of antiretroviral drugs among African populations before they can be prescribed as a frontline HIV treatment. This is a good idea, but it is unlikely that the African market is large enough for drug makers to justify additional trials from a revenue standpoint. Instead, international financial support will be needed.

Published By Datamonitor
04 Dec 2002
Expert View
Expert View

AIDS 2010: promising developments for novel HIV agents and strategies

Given the abundance of therapeutic options for HIV treatment, companies are increasingly looking to simplify therapy through the development of cross-class combinations and nucleoside-sparing strategies to minimize toxicity. Many of the pipeline drugs highlighted at this year's International AIDS Conference brought this new direction of development into focus.

Published By Datamonitor
27 Jul 2010
ResearchWire
ResearchWire

AIDS wasting: US physicians three times more likely to treat than European physicians

Published By Datamonitor
09 Nov 2001
ResearchWire
ResearchWire

AIDS wasting: US physicians three times more likely to treat than European physicians

Published By Datamonitor
06 Feb 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.